All News

Medication adherence is an ongoing and serious problem; according to the Center for Health Transformation, the annual cost of patients not taking their medicines as prescribed is nearly $300 billion, with approximately 125,000 patients dying each year due to poor adherence-that’s 342 people every day.

Provisions in the Affordable Care Act (ACA) drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011, according to research published on Wednesday.

Come Rain or Shine

Amid one of the most divisive eras in our nation’s political history, one thing we can all pretty much agree on is the fact that our stalled economic engine needs a jumpstart.

This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes.

A critical drug that has experienced shortages is Genzyme’s Fabrazyme (agalsidase beta), the only enzyme replacement therapy approved in the US for Fabry disease.

UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times.

In judging the Prometheus patents invalid, the Supreme Court may have shown its hand on the upcoming Myriad Genetics case.

The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years.

Over a hundred public companies, dozens of clinicians, and several regulators participated in investment firm Leerink Swann’s 2012 Healthcare Conference in mid-February.

One of the key reputational assets of Big Pharma is the patient assistance program [PAP], which provides patented innovative medicines to needy patients for free or at a nominal charge – it’s the industry’s own branded version of the social safety net

We thank you and your editorial staff for publishing the article titled ‘How to Choose a Medical Animator’ in the 1 February issue of Pharmaceutical Executive

Merck KGaA has announced measures intended to reduce costs and increase efficiency to ensure the long-term success of its business model

SAS’s Brad Sitler talks about the importance of incremental sales, customer proximity, and anticipating a compensation model based on health outcomes

Biotechs in Colorado, US, are enjoying a windfall of funding from Venture Capitalists who have to date invested $66.

A couple of years ago I spoke at a Life Sciences Forum organized by Oracle. The audience was 100-percent life science and IT professionals, but I spoke about the magazine business.

The Supreme Court will open up deliberations on the constitutionality of three important parts of healthcare reform (HCR) this month

Leading in Emerging Markets

PE Emedia Rates 2012

Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.

GlaxoSmithKline is recalling 394,230 bottles containing its antihypertensive drug DynaCirc CR (isradipine) controlled-release tablets, according to a Feb. 22, 2012, FDA enforcement report

In 1983-with the help of Abbey Meyers and the drive she had to help her son (more on that here)-the Orphan Drug Act was passed to incentivize pharma to step up and play an active role in drug development for the 30 million children and adults in the U.S.

With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles

Publicis Healthcare continues its expansion into Asia with this week’s announcement of its acquisition of U-Link Business Solutions (UBS), one of China’s leading agencies specializing in healthcare communications.

A new collaboration will move FDA closer to predicting adverse events – before they happen – as part of the regulatory process

All-told the Mayo Clinic’s recent pilot study on clinical trial patient recruitment using social media and online networks not only helped researchers assemble large and demographically diverse patient groups more quickly, but also less expensively than they could through other means

William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.